title: How to deal with the hyperimmunized potential recipients.
abstract: End-stage renal disease (ESRD) patients with high levels of anti-HLA panel reactive antibodies (PRA) represent an increasing group in which sensitization, induced by pregnancies, previous transplants, and blood transfusions, considerably delay the opportunity to receive a graft. Currently, more than 50% of the 4700 patients awaiting transplantation in France are sensitized, of which 33% are defined as hyperimmunized (PRA greater than = 80%), and only 9.5% of the total number of transplants have been done in highly sensitized recipients. The magnitude of this problem, similar in Europe and North America, explains why more active strategies for managing hyperimmunized patients have been introduced during the past decade. Clearly, the simplest is finding of a well-matched organ that does not carry the HLA antigens against which the recipient has generated antibody, but that is limited by the number of shared grafts. The second is the development of a new cross-matching technique prior to transplantation. Attempts at immunoregulation of secreting B cell clones have been carried out using either hypertransfusions or injection of polyclonal Ig. Finally, removal and prevention of the resynthesis of HLA antibodies is a most attractive approach using immunoadsorption (IA) system with sepharose-bound protein-A columns. In our unit, fifteen ESRD patients with high levels of PRA were treated with IA. Infectious complications were not observed after IA and transplantation, and the procedure was well tolerated. In spite of the use of adjunctive immunosuppressive treatment with cyclophosphamide and prednisolone, this method produced only variable effects in lowering PRA levels, and was hampered by high de novo resynthesis of anti-HLA antibodies.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Nephrology Unit, Centre Hospitalo-Universitaire de Bicêtre, Kremlin Bicêtre, France.
authors.forename: B M
authors.initials: BM
authors.lastname: Charpentier
authors.forename: C
authors.initials: C
authors.lastname: Hiesse
authors.forename: F
authors.initials: F
authors.lastname: Kriaa
authors.forename: P
authors.initials: P
authors.lastname: Rousseau
authors.forename: H
authors.initials: H
authors.lastname: Farahmand
authors.forename: A
authors.initials: A
authors.lastname: Bismuth
authors.forename: D
authors.initials: D
authors.lastname: Fries
mesh_terms: D000906:Antibodies / Q000302:isolation & purification; D001402:B-Lymphocytes / Q000276:immunology; D006085:Graft Survival; D006680:HLA Antigens / Q000276:immunology*; D006650:Histocompatibility Testing; D006801:Humans; D007114:Immunization; D016030:Kidney Transplantation
chemical_list: D000906:Antibodies; D006680:HLA Antigens